The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide
Abstract
The effect of various types of nanoliposomes (associated with curcumin, phosphatidic acid, cardiolipin, or GM1 ganglioside) on the aggregation of the amyloid-β(1-42) (Aβ(1-42)) peptide was investigated. Nanoliposomes incorporating curcumin (curcumin-liposomes) were prepared by adding curcumin in the lipid phase during liposome preparation, whereas curcumin surface-decorated liposomes were prepared by using a curcumin-lipid conjugate (lipid-S-curcumin liposomes) or by attaching a curcumin derivative on preformed liposomes by click chemistry (click-curcumin liposomes). The lipid ligands (phosphatidic acid, cardiolipin, or GM1) were also incorporated into nanoliposomes during their formation. All nanoliposomes with curcumin, or the curcumin derivative, were able to inhibit the formation of fibrillar and/or oligomeric Aβ in vitro. Of the three forms of curcumin liposomes tested, the click-curcumin type was by far the most effective. Liposomes with lipid ligands only inhibited Aβ fibril and oligomer formation at a very high ratio of liposome to peptide. Curcumin-based liposomes could be further developed as a novel treatment for Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“curcumin-containing nanoliposomes as well as other delivery systems have been designed and show to be very effective in reducing the Aβ fibrils formation (Taylor et al., 2011; Lazar et al., 2013; Mourtas et al., 2014; Shahbaz et al., 2021)”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Taylor et al., 2011
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Self-citationYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,802
Colorimetric determination of phospholipids with ammonium ferrothiocyanate
Stewart, J. C. M. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90269-9 · Cited by 1,786
Stability of curcumin in buffer solutions and characterization of its degradation products
Wang, Y., Pan, M., Cheng, A., Lin, L., Ho, Y., Hsieh, C., & Lin, J. (1997) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(96)02024-9 · Cited by 1,709
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature
Anand, P., Thomas, S. G., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Sung, B., Tharakan, S. T., Misra, K., Priyadarsini, K. I., Rajasekharan, K. N., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.008 · Cited by 1,205
Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,075
The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug Delivery Platform
Hong, S., Leroueil, P. R., Majoros, I., Orr, B. G., Baker, J. R., & Holl, M. M. B. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.015 · Cited by 585
Flagged first, then by citations
Cited by
Sorted by citations
Curcumin—From Molecule to Biological Function
Esatbeyoglu, T., Huebbe, P., Ernst, I. M. A., Chin, D., Wagner, A. E., & Rimbach, G. H. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107724 · Cited by 921
Lee, W., Loo, C., Bebawy, M., Luk, F., Mason, R. S., & Rohanizadeh, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040002 · Cited by 552
Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032616 · Cited by 454
Therapeutic Applications of Curcumin Nanoformulations
Yallapu, M. M., Nagesh, P. K. B., Jaggi, M., & Chauhan, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9811-z · Cited by 416
Protective effect of curcumin against heavy metals-induced liver damage
García‐Niño, W. R., & Pedraza‐Chaverrí, J. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.04.016 · Cited by 395
Metadata
- Authors
- Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., Ferla, B. L., Nicotra, F., Masserini, M., Antimisiaris, S. G., Gregori, M., & Allsop, D.
- Affiliations
- Lancaster University (GB)
- University of Patras (GR)
- University of Milano-Bicocca (IT)
- Corresponding author
- Allsop, David
- ORCID
- Venue
- Nanomedicine Nanotechnology Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 7
- Issue
- 5
- Pages
- 541-550
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2082371846
- Cited by
- 149
- References
- 46
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 10 · 2023: 9 · 2022: 13 · 2021: 9 · 2020: 12 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 4 · 2015: 10 · 2014: 17 · 2013: 9 · 2012: 10
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nanomedicine Nanotechnology Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- Funders
- Seventh Framework Programme (212043)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- curcumin, nanoliposomes, amyloid-beta 42, peptide aggregation inhibition, Alzheimer's disease, phosphatidic acid, cardiolipin, GM1 ganglioside, click chemistry, fibril formation, oligomerization, lipid ligands, nanomedicine
- MeSH terms
- Alzheimer Disease, Cardiolipins, Curcumin, G(M1) Ganglioside, Humans, Ligands, Liposomes, Peptide Fragments, Phosphatidic Acids, Amyloid beta-Peptides, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
